Lipfendra (enlicitide), the first oral PCSK9 inhibitor, lowers LDL by 60%

PCSK9 inhibitors are amazing medications that lower cholesterol by about 60% on their own, or 80-85% as part of triple therapy. Yet, only 1% of eligible patients use PCSK9 inhibitors today. Aside from cost, the biggest barrier is that they’re are all injectibles, not pills.

The FDA just approved Merck’s Lipfendra (enlicitide), the first oral PCSK9 inhibitor. Enlicitide lowered LDL by 56%-60%, about the same as injections like Repatha.

This article covers how enlicitide stacks up against statins, how much it lowers LDL and the rest of your lipid panel, what it costs, and what we know so far about insurance coverage.

Lipfendra lowered LDL cholesterol by 56-60%

Lipfendra was tested in a phase 3 trial with 2,912 adults, the CORALreef Lipids trial. Lipfendra lowered LDL cholesterol by 56% to 60% on top of existing statin therapy. That’s essentially equivalent injectable PCSK9 inhibitors, which lower LDL by about 60%.

At 24 weeks in CORALreef Lipids, enlicitide lowered LDL, non-HDL cholesterol, ApoB, and Lp(a) together.

In the trial, 67.5% of people on Lipfendra hit both a 50%-or-greater LDL drop and an LDL under 55 mg/dL, versus 1.2% on placebo. Layered on a statin, that pushes many people into the 20s and 30s mg/dL, levels a statin alone rarely reaches.

What’s more, Lipfendra moves the whole atherogenic panel, not just LDL. In the trial, it reduced Lp(a) by 28%, which is especially meaningful since the Lp(a)-specific drugs are still in clinical trials.

The ApoB and non-HDL reductions largely correspond to the LDL drop (these quantities are correlated and measure the same underlying particles in different ways).

How does Lipfendra work?

Lipfendra blocks PCSK9, a protein that destroys the liver’s LDL receptors. Those receptors are what pull LDL out of your blood. Blocking PCSK9 lets more of them survive, so the liver keeps clearing LDL instead of letting it circulate. Lipfendra his hitting the same target as injections,but the hard part was getting it into a pill. Repatha and Praluent are monoclonal antibodies, and antibodies are far too large to survive the digestive tract, so they have to be injected. Lipfendra is a macrocyclic peptide instead, a much smaller ring-shaped molecule that holds together well enough to be absorbed from the gut. Derek Lowe wrote a great write-up on the impressive chemistry behind Lipfendra here.

Why an oral PCSK9 inhibitor matters

The barrier to PCSK9 inhibitors is the injection. Roughly 6 million Americans have high LDL despite a statin, and qualify for a PCSK9 inhibitor, yet only about 1% take one. Some of that is prior authorization and cost, but a lot of it is the needle, the pharmacy trip, and refrigeration. (About 86 million US adults have high cholesterol in total, and conceivably PCSK9 inhibitors will start being used as a monotherapy as they become more convenient and cost comes down.)

All PCSK9 inhibitors before Lipfendra were injections. A pill removes the most common reason people never start.

A once-daily pill fits into the same routine as a statin. What’s more, AstraZeneca has its own oral PCSK9 inhibitor (AZD0780) in trials, so this is likely the start of a category rather than a single drug.

Lipfendra vs statins

Lipfendra and statins aren’t rivals. They’re usually taken together, and they lower ApoB and LDL by different routes. Statins tell the liver to make less cholesterol, which prompts it to pull more LDL out of the blood. Lipfendra keeps the liver’s LDL receptors alive so they can keep clearing it. Because the mechanisms differ, the effects stack, which is why CORALreef tested Lipfendra on top of a statin rather than against one. For the full comparison, see PCSK9 inhibitors vs statins.

So Lipfendra isn’t a statin replacement in the way the comparisons often imply. A high-intensity statin like atorvastatin 40-80 mg or rosuvastatin 20-40 mg lowers LDL by roughly 50% on its own, and it costs about $2 a month as a generic. Lipfendra was studied as the thing you add when that isn’t enough, and it delivered another 56-60% on top.

The nearer comparison is ezetimibe, the oral drug most people try next after a statin. Ezetimibe adds about 18-20% LDL reduction on top of a statin. Lipfendra adds roughly three times that (albeit at more than a hundred times the price).

Added to a statin, an oral PCSK9 inhibitor reaches the same LDL reduction as the injections, and goes well past what a statin or statin-plus-ezetimibe delivers.

Lipfendra side effects

Lipfendra’s side effects mostly matched placebo: adverse events in 77.7% of people versus 76.2% on placebo, no meaningful difference in serious events, and slightly fewer people stopping the drug than stopping placebo (3.1% vs 4.1%). In the separate CORALreef HeFH trial, dizziness (9% vs 4%) and diarrhea (7% vs 2%) came up more often than placebo.

How much will Lipfendra cost?

Lipfendra’s list price is $315 for a 30-day supply, or about $3,780 a year. That’s below the roughly $6,900 list price of the injectable PCSK9 inhibitors.

However, list price isn’t what most people pay. As a brand-new drug, Lipfendra won’t be on every formulary yet, and insurers are likely to wrap it in the same prior authorization they use for the injectable PCSK9 inhibitors, meaning a documented statin trial first. Whether your plan treats it as a preferred oral option or gates it like an injectable will decide your out-of-pocket cost more than the list price does. We track the rules in insurance coverage of PCSK9 inhibitors.

When will Lipfendra be available?

Lipfendra was approved on July 16, 2026. Merck hasn’t announced a date for when it reaches pharmacy shelves. Because it’s a tablet, it’ll go through ordinary retail and mail-order pharmacies (CVS, Walgreens, your local independent), with none of the specialty-pharmacy routing the injectables need. Summer 2026 is a reasonable estimate.

Lipfendra dosage and prescribing information

Lipfendra is a 20 mg tablet taken once daily. The FDA approved it as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). There’s no dose titration and no refrigeration, which is part of the practical difference from the injections. Merck’s full prescribing information has complete details.

What to ask your doctor

If your LDL or ApoB is still above target on your current regimen, these are the questions worth raising: Am I on a maximally tolerated high-intensity statin? Would adding ezetimibe get me to goal, or do my numbers warrant a PCSK9 inhibitor? Now that there’s an oral option, does that change the calculus if a shot was the sticking point? And does my plan cover Lipfendra, or does it want an injectable first?

See also: PCSK9 inhibitors lower LDL by about 60%, PCSK9 inhibitors vs statins, and insurance coverage of PCSK9 inhibitors.